Literature DB >> 10228899

More than 15 years of CA 125: what is known about the antigen, its structure and its function.

T J O'Brien1, H Tanimoto, I Konishi, M Gee.   

Abstract

In 1997 CA 125 celebrated its 15th anniversary. Since the discovery of OC 125, an antibody that recognizes CA 125, by Bob Bast and his colleagues, considerable progress has been made toward the development of more sensitive and more precise assay systems. However, a great deal of mystery still remains about the CA 125 molecule and further enlightenment will probably not come until the gene for CA 125 is cloned and the complete open reading frame for the peptide core identified. In the meantime, we have learned some structural features of the CA 125 molecule as well as a little about its regulation and the requirements for its secretion or release from epithelial derived cells in cultures. The CA 125 molecule is almost certainly a glycoprotein with a predominance of O-linkages. It is heterogeneous with regard to both size and charge, most likely due to continuous deglycosylation of side chains during its life-span in bodily fluids. It exists as a very large complex (perhaps as much as 4 million daltons) under natural conditions. The core CA 125 subunit is in excess of 200,000 daltons and it retains the capacity to bind both OC 125 class antibodies and M 11 class antibodies. As a denatured purified subspecies the CA 125 molecule appears to autoproteolyse presumably due to an endogenous protease activity inherent to the molecule. Release or secretion of CA 125 appears directly linked to the epithelial growth factor receptor signal transduction pathway. Prior to its release from cultured cells, CA 125 is phosphorylated (at either/both serine and threonine) and dephosphorylated when released. To stimulate discussion on the regulation of CA 125 synthesis, its secretion and its structural configuration, we have presented a model of a theoretical CA 125 molecule. Perhaps it will provide a focus of attention until the CA 125 gene is cloned and the real molecule is described.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10228899     DOI: 10.1177/172460089801300403

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  16 in total

Review 1.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

2.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

3.  Normalization of cancer antigen 125 after mitral valve replacement in a patient with congestive heart failure due to mitral valve endocarditis.

Authors:  Hiroki Sugishita; Hiroshi Imagawa; Kanji Kawachi; Shinnji Takano; Nobuhiro Tsunooka; Fumiaki Shikata
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-09

4.  Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

Authors:  Alena A Chekmasova; Thapi D Rao; Yan Nikhamin; Kay J Park; Douglas A Levine; David R Spriggs; Renier J Brentjens
Journal:  Clin Cancer Res       Date:  2010-07-13       Impact factor: 12.531

5.  Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation.

Authors:  H Yucel; H Kaya; A Zorlu; K Yıldırımlı; E Sancakdar; H Gunes; R Kurt; U Ozgul; O O Turgut; M B Yilmaz
Journal:  Herz       Date:  2014-09-27       Impact factor: 1.443

6.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Authors:  Nathalie Scholler; Barbara Garvik; Martha Hayden-Ledbetter; Toni Kline; Nicole Urban
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

7.  Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?

Authors:  Julio Núñez; Eduardo Núñez; Luciano Consuegra; Juan Sanchis; Vicent Bodí; Angel Martínez-Brotons; Vicente Bertomeu-González; Rocio Robles; Maria J Bosch; Lorenzo Fácila; Helene Darmofal; Angel Llàcer
Journal:  Heart       Date:  2006-12-12       Impact factor: 5.994

8.  Prognostic value of increased carbohydrate antigen in patients with heart failure.

Authors:  Ana B Méndez; Jordi Ordoñez-Llanos; Andreu Ferrero; Mariana Noguero; Teresa Mir; Josefina Mora; Antoni Bayes-Genis; Sònia Mirabet; Juan Cinca; Eulàlia Roig
Journal:  World J Cardiol       Date:  2014-04-26

9.  Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis.

Authors:  Angel Cheung; Mengqi Gong; Roberto Bellanti; Sadeq Ali-Hasan-Al-Saegh; Guangping Li; Eulàlia Roig; Julio Núñez; Thomas D Stamos; Mehmet Birhan Yilmaz; Kaya Hakki; William K K Wu; Sunny Hei Wong; Wing Tak Wong; George Bazoukis; Konstantinos Lampropoulos; Lah Ah Tse; Jichao Zhao; Gregory Y H Lip; Adrian Baranchuk; Martin C S Wong; Tong Liu; Gary Tse
Journal:  Heart Asia       Date:  2018-01-07

Review 10.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.